Literature DB >> 19387807

Femoral vascular complications following catheter ablation of atrial fibrillation.

Liza A Prudente1, J Randall Moorman, Douglas Lake, Yuping Xiao, Heather Greebaum, J Michael Mangrum, John P DiMarco, John D Ferguson.   

Abstract

BACKGROUND: Femoral vascular complications remain a significant complication of catheter ablation of atrial fibrillation as a result of peri-procedural anticoagulation protocols.
OBJECTIVE: We investigated the effect of three different anti-coagulation regimens on the incidence of femoral vascular complications following AF ablation over a 4 year period.
METHODS: We performed 603 catheter ablations in 539 patients from January 2004 to January 2008. All patients were started on coumadin immediately after procedure and received enoxaparin at 1 mg/kg 4 h post procedure and again 12 h later. Three protocols for enoxaparin, administered 12 hourly, were used post-procedure: Protocol A--1 mg/kg x ten doses; Protocol B--1 mg/kg x six doses, and Protocol C--0.5 mg/kg x six doses. We documented occurrence of femoral vascular complications prior to discharge and at the 1 month post-op visit using a prospective database. A femoral vascular complication was defined as hematoma requiring prolonged hospitalization, blood transfusion or surgical intervention.
RESULTS: There were 21 femoral vascular complications during the study period. The rate of complication fell from 5.7% (protocol A) to 1.6% (protocol C) (p < 0.03). We attribute the decrease in complication rate to the shorter anticoagulation protocol, as the reduction remained significant regardless of variation in catheter sizes. There were no new cerebral vascular events with the lower enoxaparin protocols.
CONCLUSION: A shorter course of post procedure anticoagulation protocol can reduce femoral complications without contributing to increased risk of thromboembolic events.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387807     DOI: 10.1007/s10840-009-9402-y

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  22 in total

1.  The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository.

Authors:  R G Brindis; S Fitzgerald; H V Anderson; R E Shaw; W S Weintraub; J F Williams
Journal:  J Am Coll Cardiol       Date:  2001-06-15       Impact factor: 24.094

2.  Circumferential pulmonary-vein ablation for chronic atrial fibrillation.

Authors:  Hakan Oral; Carlo Pappone; Aman Chugh; Eric Good; Frank Bogun; Frank Pelosi; Eric R Bates; Michael H Lehmann; Gabriele Vicedomini; Giuseppe Augello; Eustachio Agricola; Simone Sala; Vincenzo Santinelli; Fred Morady
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

3.  Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation.

Authors:  Hakan Oral; Aman Chugh; Mehmet Ozaydin; Eric Good; Jackie Fortino; Sundar Sankaran; Scott Reich; Petar Igic; Darryl Elmouchi; David Tschopp; Alan Wimmer; Sujoya Dey; Thomas Crawford; Frank Pelosi; Krit Jongnarangsin; Frank Bogun; Fred Morady
Journal:  Circulation       Date:  2006-08-14       Impact factor: 29.690

4.  Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period.

Authors:  Oussama M Wazni; Salwa Beheiry; Tamer Fahmy; Conor Barrett; Steven Hao; Dimpi Patel; Luigi Di Biase; David O Martin; Mohamed Kanj; Mauricio Arruda; Jennifer Cummings; Robert Schweikert; Walid Saliba; Andrea Natale
Journal:  Circulation       Date:  2007-11-12       Impact factor: 29.690

Review 5.  Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Mark N Levine; Gary Raskob; Rebecca J Beyth; Clive Kearon; Sam Schulman
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

6.  Risk factors for intracranial hemorrhage in outpatients taking warfarin.

Authors:  E M Hylek; D E Singer
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

7.  Risk of major hemorrhage for outpatients treated with warfarin.

Authors:  D A McMahan; D M Smith; M A Carey; X H Zhou
Journal:  J Gen Intern Med       Date:  1998-05       Impact factor: 5.128

8.  Phased-array intracardiac echocardiography monitoring during pulmonary vein isolation in patients with atrial fibrillation: impact on outcome and complications.

Authors:  Nassir F Marrouche; David O Martin; Oussama Wazni; A Marc Gillinov; Allan Klein; Mandeep Bhargava; Eduardo Saad; Dianna Bash; Hirotsugu Yamada; Wael Jaber; Robert Schweikert; Patrick Tchou; Ahmad Abdul-Karim; Walid Saliba; Andrea Natale
Journal:  Circulation       Date:  2003-05-19       Impact factor: 29.690

9.  Trans-septal catheterization in the electrophysiology laboratory: data from a multicenter survey spanning 12 years.

Authors:  Roberto De Ponti; Riccardo Cappato; Antonio Curnis; Paolo Della Bella; Luigi Padeletti; Antonio Raviele; Massimo Santini; Jorge A Salerno-Uriarte
Journal:  J Am Coll Cardiol       Date:  2006-02-09       Impact factor: 24.094

10.  Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.

Authors: 
Journal:  Arch Intern Med       Date:  1996-02-26
View more
  9 in total

1.  Effectiveness of a strategy to reduce major vascular complications from catheter ablation of atrial fibrillation.

Authors:  Fnu Abhishek; Edwin Kevin Heist; Conor Barrett; Stephan Danik; Dan Blendea; Christina Correnti; Zaka Khan; Jeremy N Ruskin; Moussa Mansour
Journal:  J Interv Card Electrophysiol       Date:  2011-02-19       Impact factor: 1.900

2.  Real-time ultrasound guidance reduces total and major vascular complications in patients undergoing pulmonary vein antral isolation on therapeutic warfarin.

Authors:  Christine C Tanaka-Esposito; Mina K Chung; Joellyn M Abraham; Daniel J Cantillon; Bernard Abi-Saleh; Patrick J Tchou
Journal:  J Interv Card Electrophysiol       Date:  2013-04-14       Impact factor: 1.900

Review 3.  Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation.

Authors:  Sara R Vazquez; Stacy A Johnson; Matthew T Rondina
Journal:  Thromb Res       Date:  2010-01-06       Impact factor: 3.944

4.  Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter.

Authors:  Prashant D Bhave; Bradley P Knight
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-08

5.  Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation.

Authors:  Hirosuke Yamaji; Takashi Murakami; Kazuyoshi Hina; Shunichi Higashiya; Hiroshi Kawamura; Masaaki Murakami; Shigeshi Kamikawa; Satoshi Hirohata; Shozo Kusachi
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

6.  Prevalence and Characteristics of Venous Thrombosis after Catheter Ablation of Atrial Fibrillation in Patients Receiving Periprocedural Direct Oral Anticoagulants.

Authors:  Takehito Sasaki; Kohki Nakamura; Kentaro Minami; Yutaka Take; Keiko Koyama; Eiji Yamashita; Shigeto Naito
Journal:  J Atr Fibrillation       Date:  2018-12-31

7.  Near zero vascular complications using echo-guided puncture during catheter ablation of arrhythmias: A retrospective study and literature review.

Authors:  Pier Luigi Pellegrino; Antonio Di Monaco; Francesco Santoro; Massimo Grimaldi; Girolamo D'Arienzo; Grazia Casavecchia; Riccardo Ieva; Matteo Di Biase; Massimo Iacoviello; Natale Daniele Brunetti
Journal:  J Arrhythm       Date:  2022-04-28

8.  Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay.

Authors:  Kimitake Imamura; Akihiro Yoshida; Asumi Takei; Koji Fukuzawa; Kunihiko Kiuchi; Kaoru Takami; Mitsuru Takami; Mitsuaki Itoh; Ryudo Fujiwara; Atsushi Suzuki; Tomoyuki Nakanishi; Soichiro Yamashita; Akinori Matsumoto; Ken-Ichi Hirata
Journal:  J Interv Card Electrophysiol       Date:  2013-04-14       Impact factor: 1.900

9.  Unusual timing of a common complication after pulmonary vein isolation.

Authors:  K Van Kolen; E Ströker; Y De Greef
Journal:  Neth Heart J       Date:  2017-08-01       Impact factor: 2.380

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.